Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05970783 | A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease | PHASE3 | RECRUITING | 414 | — | — | Nov 8, 2022 | Apr 1, 2025 | Oct 17, 2024 | 1 | China |
The pain disappearance referred to the Visual Analogue Scale (VAS) score becoming 0-1 points, and was no longer greater than or equal to 2 points at any subsequent evaluation. The pain disappearance rate was defined as the proportion of patients who achieved a pain disappearance after treatment.
| Arm | Type | Description |
|---|---|---|
| Jincaopian Tablets group | EXPERIMENTAL | Patients receive Jincaopian Tablets 0.6g/day for 12 weeks. |
| Placebo group | PLACEBO_COMPARATOR | Patients receive a placebo 0.6g/day for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| Jincaopian Tablets | DRUG | Jincaopian Tablets 0.2g tid p.o. |
| Placebo | OTHER | Placebo 0.2g tid p.o. |
Inclusion Criteria: * Meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease; * The average VAS score of pain in the week before enrollment is ≥4; * The McCormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 poi...